There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine -- the nation's only traditional ...

Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

Novavax's protein-only vaccine is once again expected to move from emergency approval to full approval status following a pause.

Novavax Inc. closed 73.09% below its 52-week high of $23.86, which the company achieved on June 6th.

The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine ...

Novavax stock was climbing again on Monday after the company expressed new confidence in the eventual approval of its ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from Novavax WASHINGTON -- The Trump administration's effort to impose new ...

Full approval from the FDA means a product can stay on the market even after a health emergency ends. HealthDay News — Novavax’s COVID-19 vaccine could soon receive full approval from the US ...

The U.S. FDA is asking Novavax (NASDAQ:NVAX) to conduct an additional randomized, controlled study of its COVID-19 vaccine before it will consider approving it. The prospect is a major setback for ...

You can reach Helen on Signal at hbranswell.01. Confusion over the Food and Drug Administration’s delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend when ...